Research Alliance II (Research Alliance II) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Research Alliance II is: No Data: Cannot be evaluated.

Competitive Comparison of Research Alliance II's Risk Assessment

For the Shell Companies subindustry, Research Alliance II's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Research Alliance II's Risk Assessment Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Research Alliance II's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Research Alliance II's Risk Assessment falls into.

Research Alliance II (NAS:RACB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Research Alliance II Risk Assessment Related Terms

Thank you for viewing the detailed overview of Research Alliance II's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Research Alliance II (Research Alliance II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108

Website

https://www.researchalliancecorp.com

Research Alliance Corp II is a blank check company.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky	director, officer: Chief Executive Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett	director	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond	director, officer: Chief Investment Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc	10 percent owner	200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron	director, 10 percent owner, officer: Chief Financial Officer	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience	director	C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

By Business Wire Business Wire • 04-28-2021

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire • 11-28-2022